On the last day, the Corona Remedies IPO was subscribed 144.54 times overall, the retail quota 30.39 times, the QIB 293.80 times, and the NII quota 220.18 times, respectively.
Details About Corona Remedies IPO
Corona Remedies got approval from SEBI for an IPO of ₹655.37 crores. This IPO consists of an Offer for sale up to 61,71,101 equity shares with a face value of ₹10 each. Moreover, the company has set up a price band between ₹1008 to ₹1062 per share.
In this IPO, 14 shares were available in 1 lot size for the minimum Retail category, and 182 shares were available in 13 lot sizes for the maximum retail category.
S-HNI (Min) has 196 shares in 14 lot sizes, S-HNI Max has 938 shares in 67 lot sizes, and B-HNI Min has 952 shares in 68 sizes.
To invest in this IPO, each investor category has specific investment amounts:
- Retail Investors: Minimum investment of ₹14,868 and maximum investment of ₹1,93,284.
- Small HNI (S-HNI): Minimum investment of ₹2,08,152.
- Small HNI: Maximum investment of ₹9,96,156.
- B-HNI Minimum: Minimum investment of ₹10,11,024.
Subscription duration of the Corona Remedies IPO
The Corona Remedies IPO opening date was December 8, 2025, and the closing date was December 10, 2025.
The allotment of Corona Remedies was finalized on December 11, 2025, while the IPO listing is on December 15, 2025.
About Corona Remedies IPO
Corona Remedies Limited, incorporated in August 2004, is a prominent pharmaceutical company engaged in manufacturing and selling products for women’s health, heart care, pain relief, urology, and other treatments.
As of December 2024, the company offers 67 brands across various therapeutic areas, including women’s healthcare, cardio-diabetes, pain management, urology, and multispecialty pharmaceuticals (including vitamins/minerals/nutrition, gastrointestinal, and respiratory). As per the report, among 30 others, Corona Remedies is the 2nd largest company in the Indian Pharmaceutical Market (“IPM”). The company offers a pan-India presence with 2,598 medical representatives in 22 states. It comprises 2 manufacturing facilities located in the state of Gujarat.
Corona Remedies IPO Company Financial Report
The company reported revenue of ₹1,202.35 crores in 2025 against ₹1,020.93 crores in 2024. The company reported a profit of ₹149.43 crores in 2025 against a profit of ₹90.50 crores in 2024.
